BPC-157 10mg

BPC-157, or Body Protection Compound-157, is derived from the naturally occurring protein, body protection compound (BPC), which is found in the human digestive tract. The primary function of BPC is to safeguard the gastrointestinal lining, promote healing, and facilitate blood vessel growth.

The synthetic version, BPC-157, is a pentadecapeptide composed of 15 amino acids, extracted from the larger BPC protein. Remarkably, it retains many of the curative properties observed in its parent molecule. Notably, BPC-157 exhibits beneficial effects in the following areas:

• Wound healing
• Promotion of blood vessel growth
• Influence on the coagulation cascade
• Generation of nitric oxide
• Enhancement of immune system function
• Modulation of gene expression
• Regulation of hormones, particularly within the gastrointestinal nervous system.

Source: PubChem

Sequence: Gly- Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Formula: C₆₂H₉₈N₁₅O₂₂
Molecular Weight: 1419.556 g/mol
PubChem CID: 108101

1. BPC-157 and Wound Healing

The natural role of BPC in the gastrointestinal (GI) tract is to safeguard the integrity of the mucosal barrier, providing protection to underlying tissues against the harmful effects of gastric acid, bile, and other digestive compounds essential for nutrient absorption from food. A crucial aspect of this function involves the recruitment of fibroblasts. BPC-157 exhibits a dose-dependent impact on fibroblast behavior both in culture and in vivo, leading to enhanced proliferation and migration of these cells[1]. Fibroblasts play a vital role in the healing process as they are responsible for depositing essential extracellular matrix proteins such as collagen, fibrin, elastin, and others.

2. Vascular Growth and Collateralization

BPC-157 concentration versus vascular endothelial cell growth
Source: PubMed

Cell culture studies have successfully shown that BPC-157 administration leads to the phenomenon of “vascular running.” Vascular running refers to the growth of blood vessels towards an injured or occluded area to restore blood flow to the surrounding tissue, safeguarding cellular function[9]. This unique capability of BPC-157 opens up the potential for developing an effective oral treatment for slowly developing arterial occlusions, commonly observed in conditions like atherosclerotic heart disease. In the future, this research area could potentially reduce the need for invasive surgical interventions such as stenting and coronary artery bypass grafting.

3. BPC-157 and Tendon Healing

Considering its role in fibroblast recruitment and blood vessel growth, it is not surprising that BPC-157 has demonstrated promising results in animal models of tendon, ligament, bone, and other connective tissue injuries. Tendon and ligament injuries tend to heal slowly, primarily due to limited blood supply in these tissues. The inadequate blood flow hinders the timely arrival of fibroblasts and other wound-healing cells to the injured area, leading to restricted overall repair. Both in vitro and in vivo studies involving rat tendons have revealed that BPC-157 enhances collateralization and increases fibroblast density in the context of tendon, ligament, and bone injuries. These findings suggest that BPC-157 is more effective in promoting healing in these tissues compared to bFGF, EGF, and VGF hormones[10].

Moreover, experiments employing FITC-phalloidin staining have demonstrated that BPC-157 acts as a potent stimulator of F-actin formation in fibroblasts[11]. F-actin is crucial for cell structure and function, particularly in cell migration. Analysis using western blotting has further indicated that BPC-157 enhances the phosphorylation of paxillin and FAK proteins, which are essential components of the cell migration pathway[12].

4. Antioxidant Properties

Studies conducted on rats have demonstrated that BPC-157 possesses the ability to neutralize specific oxidative stress markers, such as nitric oxide and malondialdehyde (MDA)[3]. This remarkable property makes BPC-157 a potent antioxidant, further supported by research showing its capacity to decrease the production of reactive oxygen species in the gastrointestinal tract. Additionally, investigations into the delivery of BPC-157 to the GI system using modified lactococcus lactis bacteria have shown significant increases in peptide levels in cell culture[13].

5. BPC-157 and Drug Side Effects

Often, the main challenge in medical pharmaceutical use lies in the side effects they produce. For example, NSAIDs such as ibuprofen cannot be used for extended periods due to their potential to cause gastric bleeding and increase the risk of heart attacks. A major goal in modern medical research is to find ways to mitigate side effects while preserving the desired therapeutic effects, as this could greatly enhance the benefits of various medications. Notably, BPC-157 has demonstrated its ability to counteract side effects associated with NSAIDs, certain psychiatric medications, and several heart medications.

Celecoxib-induced gastric lesions (black) in rats treated with BPC-157, saline (control), L-NAME, and L-arginine.
Source: World Journal of Gastroenterology

It is not surprising that BPC-157 is effective in preventing many of the gastrointestinal (GI) side effects associated with certain drugs. However, what is less intuitive is that this peptide also offers protection against side effects in the brain, heart, and other tissues. In rat studies, BPC-157 has shown its ability to safeguard against QTc prolongation in the heart, a condition that can lead to severe and potentially fatal arrhythmias. QTc prolongation is often caused by drugs used to treat diabetes, schizophrenia, and other psychiatric conditions[14].

Additionally, BPC-157 has demonstrated its capacity to prevent other side effects of psychiatric medications, including severe issues such as catalepsy and somatosensory disturbance[15]. This latter benefit may hold the potential to significantly improve the treatment of psychiatric conditions, which are notoriously challenging to manage, partly due to patients discontinuing their medications as a result of severe side effects.

6. BPC-157 and Bees

Colony collapse disorder (CCD) refers to a syndrome where entire honey bee colonies experience rapid decline and eventual devastation. The exact causes of this condition remain partially undefined, but one contributing factor is an infection in honey bee guts caused by the fungus Nosema ceranae. Interestingly, researchers have found that by supplementing honey bee food with BPC-157, the damage caused by the fungus in honey bee GI tracts is reduced, leading to an increase in hive survival rates[16]. These trials were conducted in natural field settings, representing a significant milestone as the first effective oral treatment to mitigate the impact of CCD on the crucial pollinator responsible for pollinating most food crops.

BPC-157 is currently undergoing active research in various cell culture and animal models. This peptide holds significant promise, not only as a therapeutic agent for promoting wound healing and regulating vascular growth, but also as a valuable tool for studying and gaining deeper insights into these intricate processes. Through research involving BPC-157, there is the potential to gain a comprehensive understanding of angiogenesis, a vital process not only crucial for wound healing but also playing essential roles in growth, cancer development, and embryogenesis.

In studies, BPC-157 has demonstrated minimal side effects, displaying moderate oral and excellent subcutaneous bioavailability in mice. It’s important to note that the dosage per kg in mice does not directly translate to humans. It’s essential to adhere to responsible practices, and BPC-157 for sale at Peptide Shop is solely intended for educational and scientific research purposes and not for human consumption. It is imperative to purchase BPC-157 only if you are a licensed researcher.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Predrag Sikiric, lead author of “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing”, and co-author of “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” is a Professor of Medical Department at University of Zagreb. Predrag Sikiric is listed in [9] and [16] under the referenced citations.

Predrag Sikiric is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

1. T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015.
2. D. Drmic et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 48, pp. 5462–5476, Dec. 2018.
3. F. Amic et al., “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 47, pp. 5366–5378, Dec. 2018.
4. A. Duzel et al., “Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights,” World J. Gastroenterol., vol. 23, no. 48, pp. 8465–8488, Dec. 2017.
5. J. Vukojević et al., “Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157,” Vascul. Pharmacol., vol. 106, pp. 54–66, 2018.
6. D. Drmic et al., “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME,” World J. Gastroenterol., vol. 23, no. 29, pp. 5304–5312, Aug. 2017.
7. M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med. Berl. Ger., vol. 95, no. 3, pp. 323–333, 2017.
8. Z. Grabarevic et al., “The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks,” J. Physiol. Paris, vol. 91, no. 3–5, pp. 139–149, Oct. 1997.
9. P. Sikiric et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1990–2001, 2018.
10. S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1972–1989, 2018.
11. C.-H. Chang, W.-C. Tsai, M.-S. Lin, Y.-H. Hsu, and J.-H. S. Pang, “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774–780, Oct. 2010.
12. Y.-L. Hu et al., “FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells,” Sci. Rep., vol. 4, p. 6024, Aug. 2014.
13. K. Škrlec et al., “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities,” Appl. Microbiol. Biotechnol., vol. 102, no. 23, pp. 10103–10117, Dec. 2018.
14. D. Strinic et al., “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats,” Life Sci., vol. 186, pp. 66–79, Oct. 2017.
15. N. Jelovac et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats,” Eur. J. Pharmacol., vol. 379, no. 1, pp. 19–31, Aug. 1999.
16. I. Tlak Gajger, J. Ribarić, M. Smodiš Škerl, J. Vlainić, and P. Sikirić, “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” J. Vet. Pharmacol. Ther., vol. 41, no. 4, pp. 614–621, Aug. 2018.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.